Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 6.2 mg (equivalent: perampanel, qty 6 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; hypromellose; purified talc; lactose monohydrate; microcrystalline cellulose; iron oxide red; magnesium stearate; povidone - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 8.3 mg (equivalent: perampanel, qty 8 mg) - tablet, film coated - excipient ingredients: purified talc; macrogol 8000; iron oxide red; iron oxide black; povidone; hypromellose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; povidone; colloidal anhydrous silica; croscarmellose sodium; crospovidone; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; croscarmellose sodium; magnesium stearate; povidone; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: povidone; crospovidone; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 400; lactose monohydrate; povidone; titanium dioxide; hypromellose; magnesium stearate; sodium starch glycollate type a - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - donepezil hydrochloride monohydrate, quantity: 5.22 mg (equivalent: donepezil hydrochloride, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin - treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - donepezil hydrochloride monohydrate, quantity: 10.43 mg (equivalent: donepezil hydrochloride, qty 10 ) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease.